Gennex Laboratories Limited (BOM:531739)

India flag India · Delayed Price · Currency is INR
10.38
-0.61 (-5.55%)
At close: Mar 9, 2026
-21.06%
Market Cap 2.52B
Revenue (ttm) 1.52B
Net Income (ttm) 191.43M
Shares Out 242.95M
EPS (ttm) 0.75
PE Ratio 13.90
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 442,781
Average Volume 303,912
Open 10.84
Previous Close 10.99
Day's Range 10.10 - 10.85
52-Week Range 10.10 - 17.25
Beta 0.26
RSI 29.04
Earnings Date Feb 14, 2026

About Gennex Laboratories

Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin for muscle relaxant; and Allopurinol, a xanthine oxidase ... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 115
Stock Exchange Bombay Stock Exchange
Ticker Symbol 531739
Full Company Profile

Financial Performance

In fiscal year 2025, Gennex Laboratories's revenue was 1.38 billion, an increase of 59.03% compared to the previous year's 867.14 million. Earnings were 181.23 million, an increase of 37.55%.

Financial Statements

News

There is no news available yet.